Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in AYA With Unresectable Residual Osteosarcoma
NCT06341712Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of cabozantinib in osteosarcoma (OS), sponsored by Ipsen. Started Nov 2024; status: terminated.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06341712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341712.